Certainly seemed in the half yearly report to be suggesting the possibility of IPP-204106 being used in combination with other cancer treatments. Anyway - interesting to hear Odey have doubled their stake and Aviva up to nearly 10% now. A real vote of confidence. DD has also previously said that he expects institutional investment to increase once phase III is underway.
By other commercial partnerships, I assume he means more than one. Most likely are Lupuzor and cancer.
Thanks for posting - sounding very confident. At the very end when he mentions other commercial milestones is he just talking about Lupuzor or other compounds in your opinion?
Sorry, almost 10% for Aviva Odey doubled their stake
Aviva bought in and have over 10% Odey also bought in Re deal talks, said what can say publicly, but due to sensitivities can't say any more at moment, but happy with the progress of the discussions Milestones: Conclusion of agreement Initiation of Phase III Then other commercial partnerships, cannot predict the time of yet, as of now
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.